Breaking News

Polpharma Fully Integrates Bioceros

To offer complete spectrum of CDMO services from discovery to commercial supply.

By: Contract Pharma

Contract Pharma Staff

In 2016, Polpharma Biologics acquired Dutch-based Bioceros and their proprietary cell line development platform CHOBC, as well as their comprehensive discovery, process development and analytical capabilities. Polpharma Biologics is now taking a further step and integrating Bioceros’ Utrecht site and their advanced cell line development capabilities fully into an already extensive biologics development and manufacturing offering, and retiring the Bioceros name. This change makes Polpharma Biolog...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters